血管内超声评价祛瘀消斑胶囊和辛伐他汀稳定易损斑块的作用

目的应用血管内超声技术（IVUS）评价祛瘀消斑胶囊和辛伐他汀对易损斑块的稳定作用。方法43只实验兔采用球囊损伤腹主动脉＋高脂饲料喂养;12周末改喂普通饲料并随机分为A（对照）、B（祛瘀消斑胶囊）、C（辛伐他汀）组,药物干预12周;24周末对3组实验兔斑块局部转染携带P53基因的腺病毒载体;26周末,应用蝰蛇毒和组胺进行药物触发。测定血脂并行体表超声、IVUS和病理学检测。结果与A组比较,B组和C组斑块破裂率显著降低（P均〈0.05）,血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）（P〈0.05～0.01）、内中膜厚度（IMT）（P均〈0.01）、斑块面积（PA）（P均〈0.01）、管腔面积狭窄率（LAS%）（P均〈0.01）、病理测量IMT（P分别〈0.05和0.01）显著降低,平均回声强度的校正值（AIIc%）（P均〈0.05）、纤维帽厚度及纤维帽/IMT比值（P〈0.05～0.01）显著升高。C组TC和LDL-C（P分别〈0.05和0.01）,IMT（P〈0.05）,PA（P〈0.05）显著低于B组。结论祛瘀消斑胶囊和辛伐他汀能有效稳定易损斑块,IVUS可为观察各种干预治疗前后斑块的稳定性和消退提供一种可靠手段。

lntravascular Ultrasound Monitoring Stabilizing Effects of Quyuxiaoban Capsule and Simvastatin on a Rabbit Model with Vulnerable Plaques

Objective To evaluate the stabilizing effects of quyuxiaoban capsule and simvastatin on vulnerable plaques.Methods Fourty-three rabbits which were fed a dietary of 1% cholesterol for 12 weeks were performed in balloon-induced abdominal aortic wall injury.These rabbits were then randomly divided into groups A,B and C.At the end of week 24,recombinant-p53 adenoviruses were locally delivered to the atherosclerotic plaques whose rupture was triggered by the intra-arterial viper venom and histamine.Serum lipids were measured and high frequency duplex IVUS imaging and pathologic staining were performed.Results Compared with group A,the incidence of plaque rupture in group B and C was significantly lower(all P<0.05);serum TC,LDL-C(P<0.05-0.01);IMT(both P<0.01),PA(both P<0.01),LAS%(both P<0.01),and pathologic measured IMT(P<0.05,0.01,respectively)in group B and C were significantly lower than that in group A;AIIc %(both P<0.05),fibrous cap thickness and fibrous cap thickness/IMT(P<0.05-0.01)in group B and C were significantly higher than that in group A;TC(P<0.05),LDL-C(P<0.01),IMT(P<0.05)and PA(P<0.05)in the group C were significantly lower than that in group B.Conclusions Quyuxiaoban capsule and simvastatin may increase the stability of atherosclerosis in a rabbit model of vulnerable plaques.Intravascular ultrasound imaging technique may provide a realiable way for the evaluation of drug treatment for vulnerable plaques.